| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: AVNC |
| Security Type |
Common Stock |
| Lead Underwriter |
Lehman Brothers |
| Days In Registration |
76 |
| Date Filed |
1-Aug-2003 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Manufacture prescription pharmaceuticals intended for final consumption, including biotech products and antibiotics |
| Revenue |
$3.6M |
| Net Income |
-$42.1M |
| Shares Outstanding (post-offering) |
22.76M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
6.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
900.0K |
| File Amount |
$78.0M |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
Current Filing Information
(Amended 29-Sep-2003) |
|
US |
|
Shares Filed |
6.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$78.0M |
| · % Change from Original |
0.0 |
| File Price Range |
$14.00 - $12.00 |
| File Mid Price |
$13.00 |
|
